
Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ:ATAI) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc. (NYSE:HTGC).
The company expects the new non-dilutive financing facility, together with the total existing cash in hand, will provide cash runway until 2025, as the flexible draw availability provides options to optimize liquidity and capital structure moving forward in ATAI’s developments.